India's Strides Pharma at near 2-year high on FDA nod for Dolutegravir

Strides Pharma Science

15/09/2023 06:33

** Shares of Strides Pharma Science  SRID.NS  rise as much
as 11.7% to 522.75 rupees, their highest level since Nov. 26,
2021
    ** The pharma co's Singapore unit got tentative approval for
Dolutegravir 50mg tablets from the U.S. Food & Drug
Administration 
    ** The HIV treatment drug complements co’s approved range of
first-line HIV treatments
    ** Dolutegravir 50mg tablet has market opportunity in the
U.S. of ~$1,345 mln, according to IQVIA
    ** More than 3.2 mln shares change hands in early trade,
8.1x the 30-day avg
    ** YTD, stock up 45.3%
    

 (Reporting by Aleef Jahan in Bengaluru)
 ((aleefjahan.cs@thomsonreuters.com))